Celltrion marks another win for its omalizumab biosimilar. The Korean firm won domestic approval from the Ministry of Food and Drug Safety for its biosimilar rival to Novartis’ Xolair.
Omlyclo, previously known as CT-P39, was approved as a treatment for allergic asthma and chronic idiopathic urticaria
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?